Haemate P

Haemate P is a prescription‑only human coagulation factor VIII/von Willebrand factor concentrate supplied as a sterile solution for injection. It contains recombinant human factor VIII and von Willebrand factor, administered intravenously to replace deficient clotting proteins. The product is marketed in the European Union and is used under medical supervision for patients with hemophilia A or von Willebrand disease and related bleeding disorders through individualized dosing.

Haemate P is indicated for the management of bleeding in patients with specific clotting factor deficiencies.

- Treatment of acute bleeding episodes in hemophilia A patients. - Routine prophylaxis to prevent spontaneous bleeds in hemophilia A. - Management of bleeding episodes in von Willebrand disease, especially type 3. - Surgical or invasive procedure support in patients with factor VIII or von Willebrand factor deficiency. - Peri‑operative hemostasis for patients undergoing major surgery.

Adverse reactions reported with Haemate P vary in frequency and severity.

Common: - Mild headache. - Fever or chills. - Infusion site erythema or pain. - Nausea. - Transient hypertension. - Fatigue.

Serious: - Anaphylactic or severe hypersensitivity reactions. - Development of inhibitors (antibodies) to factor VIII. - Thromboembolic events. - Severe hemolysis. - Acute renal failure.

Before initiating therapy with Haemate P, clinicians should consider several safety considerations.

- Assess for a history of allergic reactions to plasma‑derived products. - Screen for inhibitors to factor VIII prior to treatment. - Monitor for signs of thrombosis, especially in patients with cardiovascular risk factors. - Use caution in patients with renal or hepatic impairment. - Avoid use in patients with uncontrolled hypertension. - Evaluate pregnancy and lactation status, as safety data are limited.

Haemate P may interact with other medications that affect hemostasis or immune response.

Avoid: - Concomitant use of other factor concentrates without medical supervision. - High‑dose pro‑coagulant agents (e.g., activated prothrombin complex concentrate) that increase thrombosis risk.

Use with caution: - Antifibrinolytic agents such as tranexamic acid. - Immunosuppressive drugs that may alter inhibitor development. - Certain antibiotics (e.g., beta‑lactams) that can cause hypersensitivity.